Who
Daniel Skovronsky
Director
Company insider
Files Form 4 as: Director, Illumina; Director, Myriad Genetics; EVP, CS&PO & Pres. LRL, Eli Lilly and.
In numbers
- Trades disclosed
- 55
- Buys
- 3
- Sells
- 1
- Bought
- $2.0M
- Sold
- $4.3M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 14 Jun 2018
- Last trade
- 16 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 23 Jun 2026 | ILMN IlluminaLife-science tools | SEC FORM 4 Code A | $275K1,674 at $164.28 | filing |
| 16 Jun 2026filed 23 Jun 2026 | ILMN IlluminaLife-science tools | SEC FORM 4 Code A | $275K1,674 at $164.28 | filing |
| 4 Jun 2026filed 5 Jun 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —59,701 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —59,701 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | LLY Eli Lilly andPharmaceuticals | SEC FORM 4 Code A | $16.2M15,547.862 at $1,044.67 | filing |
| 9 Feb 2026filed 11 Feb 2026 | LLY Eli Lilly andPharmaceuticals | SEC FORM 4 Code A | $16.2M15,547.86 at $1,044.67 | filing |
| 1 Feb 2026filed 3 Feb 2026 | LLY Eli Lilly andPharmaceuticals | SEC FORM 4 Code M | —12,684 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | LLY Eli Lilly andPharmaceuticals | SEC FORM 4 Code F | $5.9M5,641.249 at $1,037.15 | filing |
| 1 Feb 2026filed 3 Feb 2026 | LLY Eli Lilly andoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —12,684 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | LLY Eli Lilly andoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —12,684 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | LLY Eli Lilly andPharmaceuticals | SEC FORM 4 Code M | —12,684 at $0.00 | filing |
| 1 Feb 2026filed 3 Feb 2026 | LLY Eli Lilly andPharmaceuticals | SEC FORM 4 Code F | $5.9M5,641.25 at $1,037.15 | filing |
| 10 Nov 2025filed 10 Nov 2025 | LLY Eli Lilly andPharmaceuticals | SEC FORM 4 Code G | —179 at $0.00 | filing |
| 12 Aug 2025filed 12 Aug 2025 | LLY Eli Lilly andPharmaceuticals | SEC FORM 4 Bought | $634K1,000 at $634.41 | filing |
| 5 Jun 2025filed 6 Jun 2025 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —49,796 at $0.00 | filing |
| 10 Feb 2025filed 12 Feb 2025 | LLY Eli Lilly andoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —12,684 at $0.00 | filing |
| 10 Feb 2025filed 12 Feb 2025 | LLY Eli Lilly andPharmaceuticals | SEC FORM 4 Sold | $3.4M3,950 at $862.69 | filing |
| 10 Feb 2025filed 12 Feb 2025 | LLY Eli Lilly andPharmaceuticals | SEC FORM 4 Sold | $294K340 at $863.97 | filing |
| 10 Feb 2025filed 12 Feb 2025 | LLY Eli Lilly andPharmaceuticals | SEC FORM 4 Sold | $615K710 at $865.76 | filing |
| 10 Feb 2025filed 12 Feb 2025 | LLY Eli Lilly andPharmaceuticals | SEC FORM 4 Code A | $16.3M18,771.75 at $868.88 | filing |
News
Why this money manager is buying Apple, Eli Lilly and selling DollaramaLLY · theglobeandmail.com · 23 Oct 2026Eli Lilly breaks ground on $5B West Creek pharma facilityLLY · richmondbizsense.com · 23 Oct 2026Eli Lilly breaks ground at Houston oral GLP-1 manufacturing siteLLY · bioxconomy.com · 23 Oct 2026
0 headlines in the last 90 days name Daniel Skovronsky; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.